Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 09, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial launch Presented interim results from ongoing RESTORE open-label extension / switch...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9
May 02, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it...
Avadel Pharmaceuticals Provides Comment on Recent Trading Activity
April 26, 2022 07:30 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a...
Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting
April 25, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the twice-nightly dosing regimen for oxybatesNocturnal adverse event questionnaires...
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
April 06, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo in adults with narcolepsyNew data bolster positive primary endpoint...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
March 22, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launch Expanded the robust portfolio of data supporting the potential impact of...
Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs
March 14, 2022 16:30 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th
March 14, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a...